Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says
Nov 15 (Reuters) - Johnson & Johnson JNJ.N is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
Under the terms of the deal being discussed, J&J could pay Ollin’s backers $2.2 billion upfront in cash and a further $1.2 billion in potential milestone payments, the FT reported.
Reuters could not immediately verify the report.